Context Therapeutics Inc. /
Link
Context Therapeutics buys CT-95 assets from Link assignment entity
What happened
Context Therapeutics Inc. acquired CT-95, formerly known as LNK-101, from Link (assignment for the benefit of creditors), LLC. CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody.
The purchase included CT-95-related assets and liabilities, for a one-time payment of $3.75 million.
The source
Everything on this page comes from the source below.
Context Therapeutics buys CT-95 assets from Link assignment entity
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly